Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 50,386 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Clear all
Completed Phase 1 Interventional

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

NCT03746041
View directory record Official record
Conditions
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Interventions
abaloparatide, bevacizumab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT01119105
View directory record Official record
Conditions
Bacterial Infections, Infection
Interventions
BC-3781, Vancomycin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects

NCT01701505
View directory record Official record
Conditions
Anesthesia
Interventions
400uL of Kovacaine Mist, 200uL of Kovacaine Mist, 120uL of Kovacaine Mist
Drug
Lead sponsor
St. Renatus, LLC
Industry
Eligibility
3 Years to 17 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 2 Interventional Results available

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

NCT01790594
View directory record Official record
Conditions
Simultaneous Kidney and Pancreas Transplantation
Interventions
Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit), Tacrolimus, Mycophenolate mofetil
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Withdrawn Early Phase 1 Interventional

Isatuximab in Lung Transplant Recipients

NCT05862766
View directory record Official record
Conditions
Antibody-mediated Rejection, Allosensitization
Interventions
Isatuximab, bone marrow biopsy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

NCT00085566
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Prostate Cancer
Interventions
everolimus, gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Hypoxia and Inflammatory Injury in Human Renovascular Hypertension

NCT02266394
View directory record Official record
Conditions
Renal Artery Stenosis, Ischemic Nephropathy, Renovascular Disease, Chronic Kidney Disease
Interventions
Mesenchymal stem cell, Mesenchymal stem cell delivery with stent placement
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients

NCT01490931
View directory record Official record
Conditions
Acute Pain
Interventions
Ketorolac Nasal Spray
Drug
Lead sponsor
Hersh, Elliot V., DMD, MS, PhD
Individual
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

NCT03685331
View directory record Official record
Conditions
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
Interventions
Palbociclib, Olaparib, Fulvestrant
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Allicin Bioavailability From Garlic Supplements and Garlic Foods

NCT00874666
View directory record Official record
Conditions
Healthy
Interventions
crushed garlic clove, garlic powder tablet
Other · Dietary Supplement
Lead sponsor
Silliker, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 23, 2026, 1:34 AM EDT
Recruiting Phase 4 Interventional

Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)

NCT07145866
View directory record Official record
Conditions
Nicotine Dependence, Transcranial Magnetic Stimulation, Vaping, Smoking Cessation, Smoking (Tobacco) Addiction
Interventions
Varenicline, Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham, Nicotine Cessation Counseling, D-cycloserine
Drug · Device · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

NCT02525094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI9929, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
North Miami Beach, Florida • Tampa, Florida • Arlington Hts, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Not applicable Interventional Results available

Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)

NCT01902966
View directory record Official record
Conditions
Cervical Cancer
Interventions
Propranolol, Diary, Relaxation Audio Recording, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics of the Hydrocodone Extended-Release Tablet (CEP-33237) in Subjects With Normal Renal Function and Subjects With Varying Degrees of Renal Impairment

NCT01319266
View directory record Official record
Conditions
Renal Impairment
Interventions
Hydrocodone Bitartrate extended-release tablet
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2012 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

NCT01189266
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Vorinostat
Radiation · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
37 Months to 21 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
174
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 129 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)

NCT02969356
View directory record Official record
Conditions
Spastic Hemiparesis
Interventions
Botulinum toxin type A, GSC
Biological · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Kansas City, Kansas • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

NCT06957756
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
BI 1584862
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed No phase listed Observational

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

NCT07644351
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 4 Interventional Results available

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251
View directory record Official record
Conditions
Bipolar Disorder, Mania, Mixed Mania
Interventions
Allopurinol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 23, 2026, 1:34 AM EDT
Terminated Phase 1 Interventional

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

NCT02514031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ARQ-761, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 2 Interventional Results available

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

NCT03699631
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 23, 2026, 1:34 AM EDT
Withdrawn Phase 2 Interventional

Phase II High-Dose Cyclophosphamide for Multiple Sclerosis

NCT00296205
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cyclophosphamide
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Oct 23, 2026, 1:34 AM EDT
Recruiting Phase 1 Interventional

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXd, Durvalumab, Cisplatin, Carboplatin, Pemetrexed, Volrustomig, Rilvegostomig
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
13
States / cities
Duarte, California • Newport Beach, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 1:34 AM EDT
Completed Phase 1 Interventional

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

NCT00894894
View directory record Official record
Conditions
Solid Tumors
Interventions
MP-470, amuvatinib (MP-470)
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 23, 2026, 1:34 AM EDT